Background
Methods
Study design
Echocardiographic measurements
Biological assays
Statistical analysis
Results
Study population
Mean values at baseline | SR group (n = 10) | AF group (n = 10) | P value |
---|---|---|---|
Age (years)
| 68.2 ± 10.6 | 66.9 ± 11.0 | NS |
Sex ratio n, (% female)
| 10 (50) | 10 (50) | NS |
Average time between the diagnosis of AF and cardioversion (weeks)
| 11.6 ± 7.7 | 14.1 ± 10.2 | NS |
Cardiac disease n, (%)
| NS | ||
Coronary disease
| 1(10) | 1(10) | |
Hypertension
| 5 (50) | 3 (33.3) | |
Diabetes mellitus
| 1 (10) | 1 (10) | |
Antiarrhthymic drugs
| NS | ||
Amiodarone
|
7
| 8 | |
Flecainide
|
1
| 1 | |
Sotalol
|
2
| 1 | |
Beta blockers
|
6
| 6 |
Echocardiographic parameters
Mean values at baseline | SR group (n = 10) | AF group (n = 10) | p |
---|---|---|---|
proANP (pmol/L)
| 235.6 ± 62.8 | 226.9 ± 151.4 | NS |
BNP (pg/mL)
| 205.9 ± 99.0 | 197 ± 139.0 | NS |
LA volume/body surface area (ml/m
2
)
| 42.3 ± 7.4 | 47.0 ± 15.7 | NS |
LVEF (%)
| 54.0 ± 11.1 | 50.5 ± 7.9 | NS |
4C-PALS (%)
| 10.9 ± 4.2 | 10.3 ± 4.7 | NS |
2C-PALS (%)
| 9.8 ± 5.1 | 11.8 ± 3.8 | NS |
MPALS (%)
| 10.4 ± 4.4 | 10.4 ± 4.4 | NS |